Trazodone History

Trazodone, a phenylpiperazine–triazolopyridine antidepressant, was originally apparent and developed in Italy in the 1960s by Appleini test laboratories. This abettor was developed according to the brainy affliction hypothesis, which was accepted from belief patients and which proposes that abasement is associated with a decreased affliction beginning 27. In adverse to added antidepressants accessible at the time of its development, trazodone approved basal furnishings on muscarinic cholinergic receptors.

In Italy, this biologic is absolutely reimbursed by the National Health System and is accessible in tablets, drops and injectable solution. Trazodone was patented and marketed in abounding countries all over the apple and became the bazaar baton in the United States during the 1980s.